VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, has announced the appointment of Raju Willener as its new chief financial officer, effective immediately. Willener brings more than three decades of international financial leadership experience across global capital markets, investment banking, corporate finance, asset management, and strategic leadership. He will report directly to CEO and Co-Founder Christoph Antz, Ph.D., and is expected to play a pivotal role in supporting the company's capital strategy, identifying strategic opportunities, and advancing its proprietary BiTAC(R) technology platform and oncology pipeline.
Willener's extensive background includes serving as director of corporate development at Exentis Group AG, where he was later appointed CFO in 2025. In that role, he led mergers and acquisitions initiatives, financial strategy, and key corporate functions. Earlier in his career, he held senior executive and investment positions, overseeing areas such as corporate finance, capital markets, investor relations, and investment portfolios exceeding CHF 30 billion in assets under management. This depth of experience is expected to be invaluable as VERAXA continues to progress its clinical development efforts.
The appointment comes at a critical time for VERAXA, which is focused on building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. The company's pipeline is powered by a suite of transformative technologies and guided by rigorous quality-by-design principles. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
According to the company, Willener's strategic insight and financial acumen will be key to navigating the complex landscape of oncology drug development and securing the resources needed to advance its pipeline. His leadership is anticipated to strengthen VERAXA's position as it moves its ADCs and proprietary BiTAC formats into clinical development and beyond. The company's BiTAC(R) technology is a registered trademark of VERAXA Biotech GmbH.
Investors and industry observers will be watching closely to see how Willener's appointment influences the company's financial trajectory and strategic decisions. With his proven track record in managing large investment portfolios and leading corporate finance initiatives, Willener is poised to make a significant impact on VERAXA's growth and long-term success.
For more information about VERAXA Biotech and its latest updates, visit the company's newsroom at http://nnw.fm/VRXA.
